Clinical Trial Update: A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of eltrombopag in pediatric patients with chronic idiopathic thrombocytopenic purpura completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenia Purpura
• Immune Thrombocytopenic Purpura

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 3 | Status: COMPLETED | Results posted: 2019-07-05